Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. boosted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 34.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,622 shares of the company’s stock after purchasing an additional 9,643 shares during the period. Envestnet Asset Management Inc.’s holdings in Denali Therapeutics were worth $767,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. grew its stake in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after acquiring an additional 885 shares in the last quarter. KBC Group NV boosted its holdings in Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after purchasing an additional 2,731 shares during the last quarter. AlphaQuest LLC grew its stake in Denali Therapeutics by 177.1% during the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock valued at $142,000 after purchasing an additional 4,449 shares in the last quarter. E Fund Management Co. Ltd. increased its holdings in Denali Therapeutics by 32.2% during the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock worth $204,000 after purchasing an additional 2,436 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Denali Therapeutics by 128.8% in the 4th quarter. SG Americas Securities LLC now owns 11,003 shares of the company’s stock valued at $224,000 after purchasing an additional 6,195 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DNLI. William Blair raised shares of Denali Therapeutics to a “strong-buy” rating in a research report on Thursday, April 24th. JPMorgan Chase & Co. decreased their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday, January 7th. Oppenheimer dropped their target price on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Robert W. Baird initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target on the stock. Finally, Baird R W raised Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Denali Therapeutics presently has an average rating of “Buy” and an average target price of $37.57.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $16.44 on Friday. The firm has a market capitalization of $2.39 billion, a PE ratio of -5.96 and a beta of 1.58. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $33.33. The business’s fifty day moving average price is $14.51 and its two-hundred day moving average price is $20.51.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. Equities research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.